On September 19, 2023 Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, reported the pre-clinical data on its CRB-701 Nectin-4 anti-drug-conjugate (ADC) will be presented at the 2023 AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper), to be held in Boston, MA October 11-15, 2023 (Press release, Corbus Pharmaceuticals, SEP 19, 2023, View Source [SID1234635258]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Details

Title:

Development of CRB-701 (SYS6002): A novel site-specific, Nectin-4 targeting ADC

Authors:

Zhaopeng Sun, Mo Dan, Lu Lv, Can Yuan, Congcong Niu, Yang Zhang, Mingyue Shen,
Xixin Hu, Xiwu Hui, Andrew Kolodziej and Rachael Brake

Abstract Number:

C121

Date/Time:

Saturday, October 14 from 12:30-4 P.M.